| Description | LY 178002 is an effective inhibitor of 5-lipoxygenase (5-LPO), phospholipase A2 (IC50: 0.6 μM for 5-lipoxygenase). LY 178002 also inhibits cellular production of LTB4 by human polymorphonuclear leukocytes and displays relatively weak inhibition on cyclooxygenase. |
| In vitro | LY178002 suppresses the generation of LTB4, PLA2 and FCO (IC50s of 0.1, 6.3 and 4.2 μM) . |
| In vivo | LY 178002 (50 mg/kg) inhibits soft tissue swelling in the uninjected paw by 81% and inhibits bone damage in rats. LY178002 (50 mg/kg; p.o.) inhibits the uninjected paw swelling by 75%, in the established FCA model. The minimum effective dose for LY178002 is 10 mg/kg p.o. |
| Target activity | 5-LPO:0.6 μM, FCO:4.2 μM, COX:, PLA2:6.3 μM |
| molecular weight | 319.46 |
| Molecular formula | C18H25NO2S |
| CAS | 107889-32-7 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| References | 1. Panetta JA, et al. The anti-inflammatory effects of LY178002 and LY256548. Agents Actions. 1989 Jun;27(3-4):300-2. |